San Diego – September 13, 2016 – Cooley advised Sophiris Bio on its $29.9 million follow-on offering of 7,475,000 common shares and warrants to purchase up to 5,606,250 common shares.
Sophiris Bio, which trades on The NASDAQ Capital Market as "SPHS,” is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases.
The corporate securities team advising Sophiris Bio included Barbara Borden, Karen Deschaine, Wade Andrews, Kristin VanderPas, Carlos Ramirez and Edmond Lay.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.